about
Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data.Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer.EGFR and K-Ras mutations in women with lung adenocarcinoma: implications for treatment strategy definition.Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis.Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer.Liver metastases from colorectal cancer: how to best complement medical treatment with surgical approaches.Dissecting signaling pathways in hepatocellular carcinoma: new perspectives in medical therapy.Bevacizumab in the pre-operative treatment of locally advanced rectal cancer: a systematic review.Trans-Arterial Radioembolization for Hepatocellular Carcinoma.Pharmacoepigenetics in gastrointestinal tumors: MGMT methylation and beyond.Second-line therapy for advanced pancreatic cancer: evaluation of prognostic factors and review of current literature.First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors.Prognostic relevance of a T-type calcium channels gene signature in solid tumours: A correlation ready for clinical validationContinuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial.Correlation between LDH levels and response to sorafenib in HCC patients: an analysis of the ITA.LI.CA database.Comment on: 'Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort'.Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma.Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction.Capecitabine after gastrectomy for advanced gastric cancer: have we got the patient right?Refractory neuroendocrine tumor-response to liposomal doxorubicin and capecitabine.FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO).Prognosis of mucinous histology for patients with radically resected stage II and III colon cancer.Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases.Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen.A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer.Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status.Bone metastases in biliary cancers: A multicenter retrospective surveySecond-line chemotherapy in advanced biliary cancer: the present now will later be pastEZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzleOptimal approach to potentially resectable liver metastases from colorectal cancerPrognostic value of CD133 caused by mutant K-Ras and B-Raf--letterFaithful markers of circulating cancer stem cells: is CD133 sufficient for validation in clinics?Genome-epigenome interactions: the Polycomb paradoxImmune Checkpoint Inhibitors in Esophageal Cancers: are we Finally Finding the Right Path in the Mist?Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world studyTotal neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trialAssociation of NOS3 and ANGPT2 gene polymorphisms with survival in patients with hepatocellular carcinoma receiving sorafenib: results of the multicenter prospective INNOVATE study
P50
Q31033443-25448B8C-FC25-43DC-89CC-46E21FB2DD34Q33555296-C93F9327-AF6A-4783-AFFA-351E635779F8Q34346624-D76C92D3-1089-4BA3-B768-AE0D45101239Q34625531-5EE9D4EE-1E4D-4698-9B36-A65505667E22Q35836756-5B3CB97B-99C5-4B32-AF37-28440F6B7F2AQ37951604-AC773B6C-E41F-4730-A893-6CFB84CF096EQ38184582-8F9A6DB2-2259-489E-BDFF-4D83A680C01BQ38216007-D0FF3E3C-ADD1-440F-8026-9DE346897124Q38591621-53F9B096-C2BE-4CFA-AFB3-13225490F7BBQ38681017-044277AA-21AC-4386-91E5-177DAFE1FC99Q38736208-0C1C1465-93A1-47E1-A5F4-CD16C537A5A9Q39869626-740A65FA-C18A-48C0-A273-ED01C5F12201Q41533087-1C99158C-A477-4808-B3F7-81D6436313CDQ41562027-FE148FE3-92C5-4459-98B1-E16A27F69473Q41754691-DE0C9184-D3F1-4E18-ADE3-60895A921F0FQ42005022-E38A9735-22CF-4849-8CE5-ADAD614DDA61Q42940352-D8F1C27D-B009-4EC7-91E8-97D6F3218087Q43125608-71BE7BCC-A825-4651-82AB-DC27E009B428Q43146760-154C9F13-BD4B-4D48-AF01-1CB4D4D6F283Q43248491-047AA8E6-FAEE-4133-BF47-311A117D4951Q43253760-5B24E8E7-A36E-4537-A162-51C8A70D99BEQ43649036-7D81A830-D80D-4DB9-8B2F-12B3760EA816Q43991765-A9E4C9B5-6146-4024-BDBA-D4330C179BF7Q46107101-1936AF36-828D-4D69-8BEB-A955C54FFAF1Q46201420-B170C530-DCAB-47AD-955B-292E11568F89Q46328545-82BD52ED-A663-4E70-9B20-99C4B80CF85FQ46852357-145C1BB4-84BB-4647-A4EF-47E6E93C778BQ56387056-D0410909-8BE2-4F57-A17A-E3FBED03D438Q56971957-D6B9835A-DC2C-4E89-8433-9EEBB2680D61Q62976255-C0D4D190-F0F5-4220-A098-17CA9A0C013DQ79620027-E229D7D7-7067-4DB2-BF20-908819FF892EQ84587772-40B31BFA-6855-4B8A-BF35-6FD0DA16FD95Q84592693-2DEFAD89-3173-4120-B4DC-8420673FB71FQ87378857-497174CF-2637-4E07-9285-B7ED9DF85352Q89977152-F8C0B012-E0F8-42A5-AAC2-EF2FE30E94C3Q90520295-C4BEB928-59D8-44C8-B767-13B987BEA44FQ91440835-ADFDFEE8-F56A-4755-B5D2-930079A3F230Q94552133-FB07362F-B255-42C6-AEA8-4C11896E0F33
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Lorenzo Fornaro
@ast
Lorenzo Fornaro
@en
Lorenzo Fornaro
@es
Lorenzo Fornaro
@sl
type
label
Lorenzo Fornaro
@ast
Lorenzo Fornaro
@en
Lorenzo Fornaro
@es
Lorenzo Fornaro
@sl
prefLabel
Lorenzo Fornaro
@ast
Lorenzo Fornaro
@en
Lorenzo Fornaro
@es
Lorenzo Fornaro
@sl
P106
P21
P31
P496
0000-0002-0187-5904